Skip to main content
. 2021 Apr 29;130(6):2009–2018. doi: 10.1152/japplphysiol.00774.2020

Figure 4.

Figure 4.

Constant work rate exercise duration while receiving dual bronchodilator vs. placebo for 48 individual subjects with COPD. COPD, chronic obstructive pulmonary disease; CWRET, constant work rate exercise time; placebo versus GFF, dual LABA/LAMA bronchodilator; GFF, glycopyrrolate/formoterol fumarate; LABA, long-acting beta agonists; LAMA, long-acting muscarinic antagonists.